Grufity logoGrufity logo
StocksFundsSearch FilingsAPI

Invitae Corp Stock Research

NVTA

0.66USD-0.01(-1.49%)Market Closed
Watchlist

Market Summary

USD0.66-0.01
Market Closed
-1.49%

NVTA Alerts

  • Big fall in Revenue (Y/Y)
  • Big jump in Earnings (Y/Y)
  • Losses in recent quarter

NVTA Stock Price

NVTA RSI Chart

NVTA Valuation

Market Cap

174.4M

Price/Earnings (Trailing)

-0.22

Price/Sales (Trailing)

0.35

EV/EBITDA

0.08

Price/Free Cashflow

-0.55

NVTA Price/Sales (Trailing)

NVTA Profitability

Operating Margin

19.88%

EBT Margin

-613.29%

Return on Equity

-3.1K%

Return on Assets

-184.23%

Free Cashflow Yield

-183.01%

NVTA Fundamentals

NVTA Revenue

Revenue (TTM)

493.9M

Revenue Y/Y

-11.78%

Revenue Q/Q

2.71%

NVTA Earnings

Earnings (TTM)

-799.7M

Earnings Y/Y

91.82%

Earnings Q/Q

-7.46%

Price Action

52 Week Range

0.633.78
(Low)(High)

Last 7 days

-14.2%

Last 30 days

-26.6%

Last 90 days

-39.9%

Trailing 12 Months

-72.9%

NVTA Financial Health

Current Ratio

2.65

NVTA Investor Care

Shares Dilution (1Y)

13.67%

Diluted EPS (TTM)

-3.76

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales

Latest Insider Trading transactions for NVTA

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
2023-06-13
Nussbaum Robert L
sold
-9,757
1.377
-7,086
chief medical officer
2023-06-13
Brida Thomas
sold
-9,747
1.377
-7,079
see remarks
2023-05-16
Wen Yafei
sold
-52,112
1.1993
-43,452
chief financial officer
2023-05-16
Brida Thomas
sold
-31,752
1.1993
-26,476
see remarks
2023-05-16
Nussbaum Robert L
sold
-31,752
1.1993
-26,476
chief medical officer
2023-05-16
Wen Yafei
sold
-86,599
1.993
-43,452
chief financial officer
2023-05-16
Knight Kenneth D.
sold
-54,486
1.1993
-45,432
chief executive officer
2023-05-16
WERNER ROBERT F.
sold
-25,855
1.1993
-21,559
chief accounting officer
2023-04-27
Osborne William H
acquired
-
-
88,027
-
2023-04-27
Crouse Geoffrey
acquired
-
-
70,422
-

1–10 of 50

Which funds bought or sold NVTA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
2023-09-20
BARCLAYS PLC
reduced
-47.83
-168,000
127,000
-%
2023-09-13
CGC Financial Services, LLC
new
-
17.00
17.00
-%
2023-09-12
Farther Finance Advisors, LLC
new
-
57.00
57.00
-%
2023-09-05
Delos Wealth Advisors, LLC
unchanged
-
-17.00
85.00
-%
2023-08-21
OSAIC HOLDINGS, INC.
added
0.41
-27,900
147,017
-%
2023-08-21
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-70.2
-297,268
98,790
-%
2023-08-16
Nuveen Asset Management, LLC
unchanged
-
-49,975
259,025
-%
2023-08-16
CreativeOne Wealth, LLC
added
78.17
163,000
338,000
0.01%
2023-08-16
Sunbelt Securities, Inc.
added
102
113
243
-%
2023-08-15
CAPTRUST FINANCIAL ADVISORS
added
1.85
-2,288
13,229
-%

1–10 of 47

Latest Funds Activity

Are funds buying NVTA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own NVTA
No. of Funds

Schedule 13G FIlings of Invitae

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Aug 30, 2023
flynn james e
4.9%
93,062,106
SC 13G
Feb 14, 2023
casdin capital, llc
3.72%
9,038,388
SC 13G/A
Feb 09, 2023
vanguard group inc
9.30%
22,587,955
SC 13G/A
Feb 03, 2023
sumitomo mitsui trust holdings, inc.
7.10%
17,256,161
SC 13G/A
Jan 25, 2023
blackrock inc.
9.0%
21,768,046
SC 13G
Feb 14, 2022
casdin capital, llc
5.39%
12,203,669
SC 13G/A
Feb 14, 2022
nikko asset management americas, inc.
8.39%
18,998,453
SC 13G/A
Feb 14, 2022
baker bros. advisors lp
4.4%
9,873,488
SC 13G/A
Feb 09, 2022
ark investment management llc
11.80%
26,700,813
SC 13G/A
Feb 04, 2022
sumitomo mitsui trust holdings, inc.
8.39%
18,998,453
SC 13G/A

Recent SEC filings of Invitae

View All Filings
Date Filed Form Type Document
Sep 25, 2023
4
Insider Trading
Sep 22, 2023
8-K
Current Report
Sep 14, 2023
3
Insider Trading
Aug 30, 2023
SC 13G
Major Ownership Report
Aug 23, 2023
8-K
Current Report
Aug 17, 2023
3
Insider Trading
Aug 14, 2023
8-K
Current Report
Aug 10, 2023
424B2
Prospectus Filed
Aug 10, 2023
424B2
Prospectus Filed
Aug 09, 2023
EFFECT
EFFECT

Peers (Alternatives to Invitae)

View All Peers In Detail
NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
273.3B
56.0B
5.43% 9.20%
31.46
4.88
-2.31% -31.27%
90.4B
9.5B
0.17% 23.71%
26.87
9.51
13.83% 5.33%
89.3B
12.7B
0.52% 19.69%
20.77
7.05
-10.94% -24.40%
13.1B
3.5B
-8.00% -12.17%
35.8
3.73
5.81% -61.22%
MID-CAP
5.2B
931.0M
-21.23% 3.57%
-10.07
5.54
28.69% 11.08%
2.9B
256.2M
-4.44% -13.77%
-15.77
11.15
2.51% -17.66%
SMALL-CAP
1.6B
328.6M
-11.64% 35.52%
-56.17
4.97
22.46% 40.27%
442.5M
167.5M
-11.33% -32.98%
-4.98
2.64
52.01% -99.69%
412.7M
309.3M
-12.49% -52.63%
-4.91
1.33
-1.76% -21.01%
325.7M
457.3M
-6.77% -21.02%
32.41
0.71
-0.61% -85.93%
211.3M
-
-3.24% 7.89%
-4.31
-
- -59.74%
174.4M
493.9M
-26.61% -72.91%
-0.22
0.35
-1.39% 74.28%
1.6M
2.8M
31.52% -41.92%
-0.04
0.56
-31.25% -41.90%

Invitae News

BioSpace
Invitae Announces Appointment of Finance Veteran Ana Schrank as ....
BioSpace,
5 hours ago
The Motley Fool
The Motley Fool

Returns for NVTA

Cumulative Returns on NVTA

-30.5%


7-Year Cumulative Returns

-47.6%


5-Year Cumulative Returns

-75.4%


3-Year Cumulative Returns

Risks for NVTA

What is the probability of a big loss on NVTA?

100%


Probability that Invitae stock will be more than 20% underwater in next one year

100%


Probability that Invitae stock will be more than 30% underwater in next one year.

86.5%


Probability that Invitae stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.

How does NVTA drawdown profile look like?

Y-axis is the maximum loss one would have experienced if Invitae was unfortunately bought at previous high price.

Drawdowns

Financials for Invitae

Income Statement (Last 12 Months)
Income Statement (Last 12 Months)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Revenue-3.2%493,878,000509,968,000516,303,000519,970,000500,829,000480,519,000460,449,000434,759,000389,092,000318,971,000279,598,000245,452,000233,235,000240,519,000216,824,000195,895,000176,750,000160,581,000147,699,000127,742,000108,524,000
  S&GA Expenses-8.9%185,230,000203,247,000218,881,000234,291,000240,599,000234,814,000225,910,000212,582,000194,881,000177,437,000168,317,000154,015,000148,905,000140,164,000122,237,000106,868,00091,769,00079,697,00074,428,00071,301,00066,956,000
  R&D Expenses-15.3%284,508,000335,830,000402,088,000462,323,000472,657,000463,965,000416,087,000356,495,000296,786,000265,295,000240,605,000219,712,000228,861,000179,200,000141,526,000106,817,00075,642,00066,124,00063,496,00060,531,00056,257,000
EBITDA100.0%--2,923,369,000-2,952,379,000-3,074,270,000-2,995,039,000-400,734,000-285,491,000-456,477,000-365,816,000-649,759,000-645,454,000-402,508,000-394,542,000-286,534,000-231,797,000------
EBITDA Margin100.0%--5.73-5.72-5.91-5.98-0.83-0.62-1.05-0.94-2.04-2.31-1.64-1.69-1.19-1.07------
Interest Expenses-14.7%46,259,00054,258,00056,747,00056,180,00056,104,00055,492,00049,900,00048,391,00040,630,00032,708,00029,766,00022,594,00019,119,00015,755,00012,412,0009,165,0008,176,0007,846,0007,030,0006,064,0005,348,000
Earnings Before Taxes74.2%-807,972,000-3,127,561,000-3,151,197,000-3,258,800,000-3,160,600,000-516,350,000-415,863,000-546,928,000-445,806,000-732,035,000-714,270,000-453,137,000-437,642,000-321,265,000-260,415,000-230,232,000-155,986,666--132,155,000-135,249,000-135,686,000
EBT Margin100.0%--6.13-6.10-6.27-6.31-1.07-0.90-1.26-1.15-2.29-2.55-1.85-1.88-1.34-1.20------
Net Income74.3%-799,667,000-3,116,617,000-3,106,293,000-3,211,600,000-3,108,620,000-451,373,000-379,006,000-408,220,000-312,946,000-613,135,000-602,170,000-444,737,000-420,542,000-302,815,000-241,965,000-194,901,000-147,917,000-130,912,000-129,355,000-140,007,000-135,686,000
Net Income Margin100.0%--6.11-6.02-6.18-6.21-0.94-0.82-0.94-0.80-1.92-2.15-1.81-1.80-1.26-1.12------
Free Cashflow100.0%--413,601,000-546,270,000-654,424,000-694,738,000-686,975,000-614,535,000-541,886,000-426,758,000-351,127,000-321,367,000-252,694,000-228,793,000-200,161,000-165,100,000------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Assets-10.0%1,5231,6921,9542,0262,2914,7684,9205,0714,9953,8733,430913970791782790503476283284239
  Current Assets-10.5%4515046937308941,0311,1791,3661,644780454415471357442509288321165167123
    Cash Equivalents38.2%2231612572173043259349221,10820413111317597.0015847325325811810654.00
  Inventory9.1%21.0019.0030.0030.0049.0043.0034.0031.0030.0031.0032.00---7.00------
  Net PPE-3.5%92.0095.0010911413313011510183.0073.0066.0046.0043.0041.0038.0032.0029.0026.0023.0029.0029.00
  Goodwill------2,2832,2832222,0611,9261,86421121151.0012710026.0050.0050.0047.00-
Liabilities-0.3%1,7241,7281,8521,8671,9051,9241,9411,9642,3411,4971,454497506465402387161160121105100
  Current Liabilities-20.1%15219010811313916814415613414612210112712182.0069.0040.0042.0036.0043.0033.00
    LT Debt, Non Current-----------------75.0075.0074.0050.0056.00
Shareholder's Equity-Infinity%-200-1021593862,8442,9783,1072,6542,3761,976417464326380404342316162179139
  Retained Earnings-4.1%-5,227-5,021-4,829-4,729-4,428-1,904-1,722-1,517-1,319-1,453-1,360-1,126-1,023-857-758-681-603-554-516-486-455
  Additional Paid-In Capital0.7%5,0184,9854,9314,8894,8154,7494,7014,6243,9733,8303,3371,5431,4871,1821,1381,086945871679666594
Shares Outstanding5.6%26425024623823222822821820419418613212910099.0096.0091.0079.0067.0064.0061.00
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Last 12 Months)
(In Millions)
Description(%) Q/Q2023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q32018Q2
Cashflow From Operations21.0%-300-379-492-586-623-617-559-497-394-325-298-232-206-179-145-113-94.64-87.68-92.22-108-114
  Share Based Compensation-14.7%15518219921317816818018818418815913013810076.0053.0030.0022.0021.0021.0020.00
Cashflow From Investing2.0%356349-174-126-190-379-204-686-672-674-400-358-370-261-2802.0025.00-1.7236.0032.006.00
Cashflow From Financing-2.2%-135-1332.008.009.001,1291,5662,0032,0101,109673231499279465478269324157143130

NVTA Income Statement

2023-06-30
Condensed Consolidated Statements of Operations - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Revenue:    
Total revenue$ 120,532$ 136,622$ 237,888$ 260,313
Operating expenses:    
Cost of revenue87,474110,340175,916207,456
Research and development63,824115,146125,802243,382
Selling and marketing44,73262,74989,242122,893
General and administrative69,96650,854115,207102,282
Goodwill and IPR&D impairment02,313,04702,313,047
Restructuring and other costs80,9984,817133,5544,817
Total operating expenses346,9942,656,953639,7212,993,877
Loss from operations(226,462)(2,520,331)(401,833)(2,733,564)
Other income (expense), net:    
Loss on extinguishment of debt, net00(10,822)0
Debt issuance costs00(19,859)0
Change in fair value of convertible senior secured notes20,619038,9230
Change in fair value of acquisition-related liabilities496,19026716,193
Other income, net4,3791,13610,2621,572
Total other income, net25,0477,32618,77117,765
Interest expense(6,020)(14,019)(17,516)(28,004)
Net loss before taxes(207,435)(2,527,024)(400,578)(2,743,803)
Income tax benefit9243,5631,88438,483
Net loss$ (206,511)$ (2,523,461)$ (398,694)$ (2,705,320)
Net (loss) income per share, basic (in dollars per share)$ (0.78)$ (10.87)$ (1.55)$ (11.75)
Net (loss) income per share, diluted (in dollars per share)$ (0.78)$ (10.87)$ (1.55)$ (11.75)
Shares used in computing net loss per share, basic263,836232,117256,910230,304
Shares used in computing net loss per share, diluted263,836232,117256,910230,304
Test revenue    
Revenue:    
Total revenue$ 115,943$ 133,182$ 228,566$ 252,679
Other revenue    
Revenue:    
Total revenue$ 4,589$ 3,440$ 9,322$ 7,634

NVTA Balance Sheet

2023-06-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 222,758$ 257,489
Marketable securities102,379289,611
Accounts receivable85,61096,148
Inventory20,81430,386
Prepaid expenses and other current assets19,66419,496
Total current assets451,225693,130
Property and equipment, net92,091108,723
Operating lease assets74,718106,563
Restricted cash10,50810,030
Intangible assets, net873,9241,012,549
Other assets20,57323,121
Total assets1,523,0391,954,116
Current liabilities:  
Accounts payable23,06713,984
Accrued liabilities107,95174,388
Operating lease obligations16,43614,600
Finance lease obligations4,5145,121
Total current liabilities151,968108,093
Operating lease obligations, net of current portion139,630134,386
Finance lease obligations, net of current portion1,6043,780
Debt0122,333
Convertible senior notes, net1,170,6111,470,783
Convertible senior secured notes (at fair value)249,5710
Deferred tax liability6,2008,130
Other long-term liabilities4,2414,775
Total liabilities1,723,8251,852,280
Commitments and contingencies
Stockholders’ (deficit) equity:  
Common stock2725
Accumulated other comprehensive income (loss)8,910(80)
Additional paid-in capital5,018,1124,931,032
Accumulated deficit(5,227,835)(4,829,141)
Total stockholders’ (deficit) equity(200,786)101,836
Total liabilities and stockholders’ (deficit) equity$ 1,523,039$ 1,954,116
Sean E. George
3000
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was incorporated in 2010 and is headquartered in San Francisco, California.